This study investigates pancreatic cancer. It looks at how an investigational medication works with radiation and chemotherapy.
The study evaluates the safety and effectiveness of the investigational medication when combined with other treatments. It checks how well patients can tolerate this combination.
- Who can participate: Adults with pancreatic ductal adenocarcinoma who have not received prior radiotherapy and have an ECOG status of 0 or 1 may be eligible. Participants should have a life expectancy of at least 3 months and adequate organ function.
- Study details: Participants will receive an investigational medication along with radiation and chemotherapy.